Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio, Inc. (BLTE) will participate in a Key Opinion Leader Webinar to discuss Stargardt Disease and Geographic Atrophy and share insights on Tinlarebant, a novel therapeutic. The webinar, moderated by Cantor Fitzgerald, will feature Dr. Michel Michaelides, a renowned expert. Tinlarebant is a promising treatment with Fast Track, Rare Pediatric Disease, and Orphan Drug designations.
Belite Bio presented additional analysis from a Phase 2 study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting. The 24-month trial showed promising results in slowing lesion growth and stabilizing visual acuity. Genetic profiling revealed that despite severe ABCA4 variants, 42% of treated subjects did not develop atrophic retinal lesions. A novel lesion size quantification method was able to detect atrophic lesions more accurately. The drug is now being evaluated in Phase 3 trials for Stargardt Disease and Geographic Atrophy.
Belite Bio presented promising data on Tinlarebant, an oral tablet aimed at slowing disease progression in patients with retinal diseases at ARVO 2024. The Phase 2 trial showed a significant reduction in atrophic lesion growth in STGD1 patients compared to standard treatment. Enrollment for Phase 3 trials is complete, with interim data expected in Q4 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.